Use of short chain fatty acids for the treatment and prevention of diseases and disorders
The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
1. A method of causing disappearance of a psoriatic lesion in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises in a unit dosage form:
a) a therapeutically-effective amount of butyric acid or a pharmaceutically-acceptable salt thereof;
b) a therapeutically-effective amount of propionic acid or a pharmaceutically-acceptable salt thereof;
c) a therapeutically-effective amount of an inorganic magnesium salt; and
d) a therapeutically-effective amount of Vitamin D3,
wherein the unit dosage form does not comprise a fatty acid that has at least five carbon atoms, and wherein the disappearance of the psoriatic lesion occurs within about three weeks of administration of the unit dosage form to the subject.
2. The method of claim 1 , wherein the administering is oral.
3. The method of claim 1 , wherein the therapeutically-effective amount of butyric acid or the pharmaceutically-acceptable salt thereof is about 800 mg.
4. The method of claim 1 , wherein the therapeutically-effective amount of propionic acid or the pharmaceutically-acceptable salt thereof is about 50 mg.
5. The method of claim 1 , wherein the therapeutically-effective amount of the inorganic magnesium salt is about 10 mg.
6. The method of claim 1 , wherein the therapeutically-effective amount of Vitamin D3 is about 50 IU.
7. The method of claim 1 , wherein the administering is three times a day for at least one week.
8. The method of claim 1 , wherein the administering is three times a day for at least one week, wherein the administering is oral, wherein the therapeutically-effective amount of butyric acid or the pharmaceutically-acceptable salt thereof is about 800 mg, wherein the therapeutically-effective amount of propionic acid or the pharmaceutically acceptable salt thereof is about 50 mg, wherein the therapeutically-effective amount of the inorganic magnesium salt is about 10 mg, and wherein the therapeutically-effective amount of Vitamin D3 is about 50 IU.
9. A method of causing disappearance of a psoriatic lesion in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises in a unit dosage form, a combination of fatty acids, wherein the combination of fatty acids consists of about 800 mg butyric acid or a pharmaceutically-acceptable salt thereof; and about 50 mg propionic acid or a pharmaceutically-acceptable salt thereof, wherein the disappearance of the psoriatic lesion occurs within about 3 weeks of administration to the subject of the unit dosage form.
10. The method of claim 9 , wherein the unit dosage form further comprises a therapeutically-effective amount of an inorganic magnesium salt.
11. The method of claim 10 , wherein the therapeutically-effective amount of the inorganic magnesium salt is about 10 mg.
12. The method of claim 9 , wherein the unit dosage form further comprises a therapeutically-effective amount of Vitamin D3.
13. The method of claim 12 , wherein the therapeutically-effective amount of Vitamin D3 is about 50 IU.
14. The method of claim 9 , wherein the administering is oral.
15. The method of claim 9 , wherein the administering is three times a day for at least one week.